✨ Agricultural Compounds Notices
NEW ZEALAND GAZETTE, No. 72 — 18 AUGUST 2016
Dated at Wellington this 12th day of August 2016.
MAREE ZINZLEY, Manager Approvals Operations, Ministry for Primary Industries (acting under delegated authority).
2016-go4757
Notice of Reassessment of Registered Trade Name Products (Notice No. MPI 675)
Maree Zinzley, Manager Approvals Operations of the Ministry for Primary Industries (MPI), acting under delegated authority from the Director-General of MPI, gives notice, under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 ("Act"), that the following applications have been made to reassess the following trade name products under section 29 of the Act:
Trade Name: TeatSeal
Reference: A007294
Active Ingredient and Concentration:
Bismuth subnitrate 2.6g per 4.0g syringe
Formulation Type: Intramammary suspension
General Use Claim:
For the prevention of mastitis during the non-lactating (dry) period.
Use Claims Impacted by the Reassessment:
- For the prevention of mastitis during the non-lactating (dry) period in lactating heifers (first calvers) and cows with somatic cell counts (SCC) of less than 120,000 and 150,000 respectively.
- For the prevention of mastitis during the non-lactating (dry) period in cows and heifers with a higher SCC immediately following treatment with Orbenin Enduro (A6036) or Orbenin Dry Cow (A0888).
- For the prevention of peri-calving mastitis in maiden heifers.
The applicant’s address for service is:
Zoetis New Zealand Limited, Level 5, 8 Mahuhu Crescent, Auckland Central, Auckland 1010. Postal Address: PO Box 2094, Auckland 1140.
Trade Name: DC Duo
Reference: A011025
Active Ingredients and Concentrations:
Cloxacillin 500mg as the benzathine salt per 8.5g syringe
Ampicillin 250mg as the Trihydrate per 8.5g syringe
Bismuth subnitrate 2.6g per 8.5g syringe
Chlorhexidine 20mg per 8.5g syringe
Formulation Type: Intramammary suspension
General Use Claim:
For the treatment and prevention of mastitis in cows at drying off.
Use Claim Impacted by the Reassessment:
Formulated for use in the dairy cow at the point of drying off, that is, as soon as possible after the last milking of lactation in order to treat existing mastitis and to provide protection against further infections during the dry period.
The applicant’s address for service is:
Bayer New Zealand Limited, 3 Argus Place, Hillcrest, Auckland 0627. Postal Address: PO Box 2825, Shortland Street, Auckland 1140.
53
Next Page →
NZ Gazette 2016, No 72
✨ LLM interpretation of page content
🌾 Notice of Reassessment of Registered Trade Name Products
🌾 Primary Industries & Resources12 August 2016
Agricultural Compounds, Veterinary Medicines, Reassessment, TeatSeal, DC Duo, Mastitis Prevention
- Maree Zinzley, Manager Approvals Operations, Ministry for Primary Industries